BSX · News · 20261030N

Guidance / Outlook

BOSTON SCIENTIFIC CORP · 2026-10-30 · Importance 20 · Surprise 24

Oppenheimer downgraded Boston Scientific from Outperform to Perform, citing growth concerns following the company’s third-quarter results. The report says the company is projected to have no growth in 2027, but does not quantify the projection or identify the revenue or other metric involved. This is an analyst outlook, not company-issued guidance.

Key facts

• The Zacks Consensus Estimate for Boston Scientific's current-year earnings was revised 2.4% downward over the last 60 days. source
• Oppenheimer projected a no-growth year for Boston Scientific in 2027. source